Bain Capital’s Life Sciences arm is relaunching a shelved immunology pipeline from Bristol Myers Squibb through a new startup, Beeline Medicines. The venture is structured around five licensed assets and is positioned to develop them as potentially differentiated treatments. In a separate development, STAT also reported the startup has now named leadership and set an initial clinical focus, including plans to move toward data readouts from a planned Phase 2 effort. The early strategy targets inflammatory and immune-mediated indications with a near-term path to generate clinical evidence.